U.S. Markets closed

FDA rejects Trevena's new opioid pain drug application; stock falls by 35 percent

John George
FDA rejects Trevena's new opioid pain drug application; stock falls by 35 percent

Trevena says it plans to continue to work with the FDA to address the issues that caused the agency to reject the company's new drug application for Olinvo.